Revisiting current National Comprehensive Cancer Network (NCCN) high-risk prostate cancer stratification: a National Cancer Database analysis

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  A. D'Amico,et al.  NCCN Guidelines Insights: Prostate Cancer, Version 1.2021. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  H. G. van der Poel,et al.  Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis , 2020, Frontiers in Oncology.

[4]  B. Mahal,et al.  Validation of a subclassification for high‐risk prostate cancer in a prospective cohort , 2020, Cancer.

[5]  J. Ciezki,et al.  Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy. , 2019, Brachytherapy.

[6]  B. Mahal,et al.  Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. , 2019, International journal of radiation oncology, biology, physics.

[7]  Misop Han,et al.  Outcomes of very high‐risk prostate cancer after radical prostatectomy: Validation study from 3 centers , 2018, Cancer.

[8]  M. Terris,et al.  Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH , 2017, The Prostate.

[9]  O. Ogawa,et al.  Subclassification of high-risk clinically organ-confined prostate cancer for early cancer-specific mortality after radical prostatectomy. , 2016, Japanese journal of clinical oncology.

[10]  Ming-Hui Chen,et al.  Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients. , 2015, International journal of radiation oncology, biology, physics.

[11]  F. Montorsi,et al.  Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. , 2015, European urology.

[12]  David C. Miller,et al.  Prostate Cancer,,Version 2.2014 Clinical Practice Guidelines in Oncology , 2014 .

[13]  Mark W. Ball,et al.  Very high risk localized prostate cancer: definition and outcomes , 2013, Prostate Cancer and Prostatic Disease.

[14]  P. Austin.  The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments , 2013, Statistics in medicine.

[15]  P. Warde,et al.  Pre-treatment risk stratification of prostate cancer patients: A critical review. , 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[16]  B. Tombal,et al.  Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. , 2010, European urology.

[17]  P. Austin.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.

[18]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .